Roberto Iacone, Alentis Therapeutics CEO
Alentis nabs $181M to broaden Claudin's scope in ADCs
Swiss biotech Alentis Therapeutics thinks it can expand the reach of the Claudin family in oncology, and half a dozen new investors are helping back …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.